The 10-second takeaway
For the quarter ended March 31 (Q1), IDEXX Laboratories beat expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share expanded significantly.
Margins grew across the board.
IDEXX Laboratories reported revenue of $322.7 million. The 10 analysts polled by S&P Capital IQ looked for revenue of $314.7 million on the same basis. GAAP reported sales were 10% higher than the prior-year quarter's $292.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.72. The 11 earnings estimates compiled by S&P Capital IQ predicted $0.71 per share. GAAP EPS of $0.72 for Q1 were 16% higher than the prior-year quarter's $0.62 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 54.2%, 130 basis points better than the prior-year quarter. Operating margin was 18.7%, 40 basis points better than the prior-year quarter. Net margin was 12.6%, 10 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $340.1 million. On the bottom line, the average EPS estimate is $0.90.
Next year's average estimate for revenue is $1.31 billion. The average EPS estimate is $3.08.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 216 members out of 227 rating the stock outperform, and 11 members rating it underperform. Among 71 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 70 give IDEXX Laboratories a green thumbs-up, and one gives it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on IDEXX Laboratories is hold, with an average price target of $85.94.
The health-care investing landscape is littered with also-rans and a few major winners. Is IDEXX Laboratories performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add IDEXX Laboratories to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
IDEXX Laboratories, Inc. Puts Long-Term Profits Ahead of Short-Term Revenue
Instrument placements gave birth to sales of high-margin consumables.
IDEXX Laboratories, Inc.'s Investors Look the Gift Horse in the Mouth
It was a solid quarter for the animal diagnostic company, but investors are worried that guidance wasn't raised enough.
IDEXX Laboratories, Inc. Earnings: Solid Revenue and Earnings Growth
Management is raising revenue guidance for the year.